Correction:
Any dermatologist will tell you ... There is no truly effective antifungal on the market...current leading treatment (Terbinafine Hydrochloride) is:
1. temporary at best, if proves effective (fungus will come back) in time, and
2. Highly toxic...in order to be prescribed this leading prescription it can only be taken for 30 days and then you need to have a liver test to make sure no damage to the liver. (and every 30 days thereafter)
Brilacidin has proven to be have NO TOXICITY...any derivative from it would likely have none.
PS. Fox is down the road the U of Penn and one of the founders of Brilacidin / PolyMedix remains there. IMO there High degree of success!!! ...
Richard W. Scott, Ph.D., Vice President, Research
Dr. Scott has spent over 28 years in the pharmaceutical industry and has extensive experience in multiple disciplines including microbiology, anti-infectives, acute coronary care, neurobiology and animal model development. He began his career as a Principal Investigator in Central Research Development at E.I. Dupont deNemours and then moved to Cephalon, Inc. in 1991 where he held positions of increasing responsibility prior to becoming Vice President of Neurobiology. He led groups involved in recombinant expression of target gene products, establishment of transgenic and gene-targeted animal models of neurodegenerative disease processes, and drug discovery in signal transduction pathways. In 2002, he co-founded PolyMedix, a company focused on the development non-peptidic mimics of the host defense proteins for infectious disease and cardiovascular disorders. He led the research team responsible for the identification and selection of the clinical lead compound, brilacidin, that successfully completed a Phase 2 clinical study for treatment of acute bacterial skin and skin structure infections (ABSSSI) and identified a potent antagonist of heparin and low molecular weight heparins (delparantag) that also reached Phase 2 clinical study. Additional programs in the research group that were supported by grants from the NIH, NSF and Departments of Defense included the development of antimicrobial mimetics for treatment of Gram-negative infections, oral and disseminated Candidiasis, malaria and food-borne infections. Dr. Scott is an author on over 67 peer-reviewed journal articles and book chapters, and is an inventor on 8 US patents.
News 
Market Data 
Discover 
